The clinical trials: randomized Aldactone evaluation study (RALES) and eplerenone post-acute myocardial infarction heart and survival study (EPHESUS), evaluated the role of mineralocorticoid receptors (MR) antagonism in patients with heart failure and patients with acute myocardial infarction, respectively. Here, NR3C2 is linked to myocardial infarction.